Evidence map›Paper›PMID 38664300›Full record

Trial reportMolecular neurobiology2024

miR-9-5p is Downregulated in Serum Extracellular Vesicles of Patients Treated with Biperiden After Traumatic Brain Injury.

Beatriz Enguidanos Villena-Rueda, Gustavo Satoru Kajitani, Vanessa Kiyomi Ota, Jessica Honorato-Mauer, Marcos Leite Santoro, Amanda Victória Gomes Bugiga, Joice Santos Rosa, Paula Fontes Asprino, Paula Meneghetti, Ana Claudia Torrecilhas and 6 more

Abstract readRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in Molecular neurobiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Unveiling the predictive power of biomarkers in traumatic brain injury: A narrative review focused on clinical outcomes.Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia · 2025
    Review
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Beatriz Enguidanos Villena-RuedaGenetics Division, Department of Morphology and Genetics, Universidade Federal de São Paulo (UNIFESP), Rua Botucatu, 740, Vila Clementino, São Paulo, - 04023900, Brazil.
Gustavo Satoru KajitaniGenetics Division, Department of Morphology and Genetics, Universidade Federal de São Paulo (UNIFESP), Rua Botucatu, 740, Vila Clementino, São Paulo, - 04023900, Brazil.
Vanessa Kiyomi OtaGenetics Division, Department of Morphology and Genetics, Universidade Federal de São Paulo (UNIFESP), Rua Botucatu, 740, Vila Clementino, São Paulo, - 04023900, Brazil.
Jessica Honorato-MauerGenetics Division, Department of Morphology and Genetics, Universidade Federal de São Paulo (UNIFESP), Rua Botucatu, 740, Vila Clementino, São Paulo, - 04023900, Brazil.
Marcos Leite SantoroLiNC - Laboratory of Integrative Neuroscience, Universidade Federal de São Paulo (UNIFESP), São Paulo, Brazil.
Amanda Victória Gomes BugigaGenetics Division, Department of Morphology and Genetics, Universidade Federal de São Paulo (UNIFESP), Rua Botucatu, 740, Vila Clementino, São Paulo, - 04023900, Brazil.
Joice Santos RosaLiNC - Laboratory of Integrative Neuroscience, Universidade Federal de São Paulo (UNIFESP), São Paulo, Brazil.
Paula Fontes AsprinoMolecular Oncology Center, Hospital Sírio-Libanês, São Paulo, Brazil.
Paula MeneghettiLaboratório de Imunologia Celular E Bioquímica de Fungos E Protozoários, Instituto de Ciências Ambientais, Químicas e Farmacêuticas, Department of Pharmaceutical Sciences, Universidade Federal de São Paulo (UNIFESP), São Paulo, Brazil.
Ana Claudia TorrecilhasLaboratório de Imunologia Celular E Bioquímica de Fungos E Protozoários, Instituto de Ciências Ambientais, Químicas e Farmacêuticas, Department of Pharmaceutical Sciences, Universidade Federal de São Paulo (UNIFESP), São Paulo, Brazil.
Paula IntasquiHuman Reproduction Section, Division of Urology, Department of Surgery, Universidade Federal de São Paulo (UNIFESP), São Paulo, Brazil.
Ricardo Pimenta BertollaHuman Reproduction Section, Division of Urology, Department of Surgery, Universidade Federal de São Paulo (UNIFESP), São Paulo, Brazil.
Maira Licia ForestiDepartment of Physiology, Universidade Federal de São Paulo (UNIFESP), São Paulo, Brazil.
Maria da Graça Naffah-MazzacorattiDepartment of Physiology, Universidade Federal de São Paulo (UNIFESP), São Paulo, Brazil.
Luiz Eugênio Araújo de Moraes MelloDepartment of Physiology, Universidade Federal de São Paulo (UNIFESP), São Paulo, Brazil.
Sintia Iole BelangeroGenetics Division, Department of Morphology and Genetics, Universidade Federal de São Paulo (UNIFESP), Rua Botucatu, 740, Vila Clementino, São Paulo, - 04023900, Brazil. sinbelangero@gmail.com.

Funding

Coordenação de Aperfeiçoamento de Pessoal de Nível Superior 001Fundação de Amparo à Pesquisa do Estado de São Paulo 2018/24561-5Fundação de Amparo à Pesquisa do Estado de São Paulo 2021/14564-0Fundação de Amparo à Pesquisa do Estado de São Paulo 2022/14055-0
6 · The paper itself

Abstract

Traumatic brain injury (TBI) is a prevalent and debilitating condition, which often leads to the development of post-traumatic epilepsy (PTE), a condition that yet lacks preventive strategies. Biperiden, an anticholinergic drug, is a promising candidate that has shown efficacy in murine models of PTE. MicroRNAs (miRNAs), small regulatory RNAs, can help in understanding the biological basis of PTE and act as TBI- and PTE-relevant biomarkers that can be detected peripherally, as they are present in extracellular vesicles (EVs) that cross the blood-brain barrier. This study aimed to investigate miRNAs in serum EVs from patients with TBI, and their association with biperiden treatment and PTE. Blood samples of 37 TBI patients were collected 10 days after trauma and treatment initiation in a double-blind clinical trial. A total of 18 patients received biperiden, with three subjects developing PTE, and 19 received placebo, with two developing PTE. Serum EVs were characterized by size distribution and protein profiling, followed by high-throughput sequencing of the EV miRNome. Differential expression analysis revealed no significant differences in miRNA expression between TBI patients with and without PTE. Interestingly, miR-9-5p displayed decreased expression in biperiden-treated patients compared to the placebo group. This miRNA regulates genes enriched in stress response pathways, including axonogenesis and neuronal death, relevant to both PTE and TBI. These findings indicate that biperiden may alter miR-9-5p expression in serum EVs, which may play a role in TBI resolution.

Indexed as

Brain Injuries, TraumaticDown-RegulationExtracellular VesiclesMicroRNAsAdultDouble-Blind MethodEpilepsy, Post-TraumaticFemaleHumansMaleMiddle AgedYoung AdultMicroRNAsMIRN92 microRNA, humanAnticholinergicExtracellular vesiclemicroRNAPost-traumatic epilepsyTraumatic brain injury

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.